CMND
Clearmind Medicine·NASDAQ
--
--(--)
--
--(--)
CMND Profile
Clearmind Medicine Inc.
A pharmaceutical company developing a new psychedelic drug
Life Science Tools and Services
07/18/2017
11/15/2022
NASDAQ Stock Exchange
3
10-31
Common stock
101–1220 West 6th Avenue, Vancouver, British Columbia V6H1A5
--
Clearmind Medicine Inc., incorporated in British Columbia on July 18, 2017, is a clinical-stage pharmaceutical company dedicated to advancing the development of novel psychedelic drugs to address prevalent but under-treated health conditions, focusing on alcohol use disorder (AUD). The company's proprietary compound, MEAI, is a non-hallucinogenic neuroplastin that is being investigated for its potential to treat AUD, binge drinking, eating disorders and metabolic conditions, as well as as as an alcohol substitute for consumers. Clearmind aims to provide innovative, safe, and effective treatments that can reduce the global economic and health burden associated with drinking, which kills millions of people every year and incurs significant health care costs. The company completed a series of IND-enabling preclinical studies in the United States and China, including pharmacokinetic, toxicological and metabolic studies in animal models to evaluate the safety and efficacy of MEAI. Clinical progress includes obtaining approval from the Israeli Ministry of Health and the U.S. FDA to start the first human phase I/II trial of AUD using CMND-100, which was conducted at leading research centers such as Yale University, Johns Hopkins University, and multiple sites in Israel such as Sourasky and Hadassah Medical Center in Tel Aviv, Israel. The company's ongoing research supports its mission to develop translational therapies for mental health and substance-related diseases.
